Enovis (NYSE:ENOV) Issues FY 2026 Earnings Guidance

Enovis (NYSE:ENOV) issued an update on its FY 2026 earnings guidance on Thursday morning. The company provided EPS guidance of 3.520-3.730 for the period, compared to the consensus EPS estimate of 3.630. The company issued revenue guidance of $2.3 billion-$2.4 billion, compared to the consensus revenue estimate of $2.3 billion.

Enovis Trading Down 2.7%

ENOV traded down $0.73 during trading hours on Friday, reaching $26.52. The company’s stock had a trading volume of 847,977 shares, compared to its average volume of 1,017,184. Enovis has a fifty-two week low of $21.00 and a fifty-two week high of $37.85. The stock has a market cap of $1.53 billion, a PE ratio of -1.28 and a beta of 1.41. The business’s 50-day moving average is $23.86 and its 200-day moving average is $25.80. The company has a debt-to-equity ratio of 0.85, a current ratio of 2.02 and a quick ratio of 1.04.

Enovis (NYSE:ENOV) last released its quarterly earnings data on Thursday, May 7th. The company reported $0.89 EPS for the quarter, beating analysts’ consensus estimates of $0.82 by $0.07. Enovis had a positive return on equity of 8.74% and a negative net margin of 52.69%.The firm had revenue of $589.15 million for the quarter, compared to analysts’ expectations of $572.02 million. During the same period in the prior year, the firm posted $0.81 earnings per share. The firm’s quarterly revenue was up 5.4% on a year-over-year basis. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. As a group, equities research analysts predict that Enovis will post 3.62 earnings per share for the current fiscal year.

Analyst Ratings Changes

ENOV has been the topic of a number of recent analyst reports. Needham & Company LLC upped their price objective on Enovis from $49.00 to $52.00 and gave the company a “buy” rating in a report on Thursday, February 26th. Zacks Research upgraded Enovis from a “hold” rating to a “strong-buy” rating in a report on Wednesday, March 4th. Evercore reiterated an “outperform” rating and issued a $36.00 price objective on shares of Enovis in a report on Friday. Wall Street Zen cut Enovis from a “buy” rating to a “hold” rating in a report on Saturday, May 2nd. Finally, Wells Fargo & Company decreased their price objective on Enovis from $42.00 to $40.00 and set an “overweight” rating on the stock in a report on Friday. One investment analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $46.57.

Insider Transactions at Enovis

In other news, insider Oliver Engert bought 1,000 shares of the firm’s stock in a transaction that occurred on Friday, February 27th. The shares were purchased at an average price of $25.50 per share, with a total value of $25,500.00. Following the purchase, the insider owned 43,640 shares in the company, valued at approximately $1,112,820. The trade was a 2.35% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Over the last quarter, insiders bought 5,000 shares of company stock worth $121,983. 2.90% of the stock is currently owned by corporate insiders.

Trending Headlines about Enovis

Here are the key news stories impacting Enovis this week:

• Positive Sentiment: Q1 results beat consensus — Enovis reported $0.89 EPS vs. $0.82 expected and revenue of $589.2M vs. $572.0M expected; revenue grew ~5.4% year-over-year, supporting the operational story. Enovis Announces First Quarter 2026 Results
• Positive Sentiment: Management reaffirmed 2026 free cash‑flow conversion of >25% despite Middle East and tariff headwinds — a sign of resilience in cash generation that can support deleveraging and shareholder returns if sustained. Enovis reaffirms 2026 free cash flow conversion
• Neutral Sentiment: FY‑2026 guidance roughly in line with expectations — the company set EPS guidance of $3.520–3.730 (consensus ~3.63) and revenue guidance of $2.3–2.4B (in line with consensus). Guidance is not a clear beat and leaves execution risk. View Press Release / Slide Deck
• Neutral Sentiment: Wells Fargo trimmed its price target from $42 to $40 but kept an “overweight” rating — the PT cut reduces implied upside slightly but the firm remains constructive on the name. Wells Fargo lowers Enovis price target
• Negative Sentiment: Conference materials flag a negative net margin — the reported negative net margin (~52.7%) signals one-time items or restructuring/other charges that could pressure near‑term profitability and investor sentiment until margins normalize. Enovis Q1 earnings report & transcript

Hedge Funds Weigh In On Enovis

Several hedge funds have recently bought and sold shares of ENOV. AQR Capital Management LLC lifted its stake in Enovis by 12.5% during the 1st quarter. AQR Capital Management LLC now owns 63,671 shares of the company’s stock worth $2,363,000 after acquiring an additional 7,072 shares in the last quarter. Goldman Sachs Group Inc. lifted its stake in Enovis by 37.6% during the 1st quarter. Goldman Sachs Group Inc. now owns 267,617 shares of the company’s stock worth $10,226,000 after acquiring an additional 73,116 shares in the last quarter. Empowered Funds LLC lifted its stake in Enovis by 13.0% during the 1st quarter. Empowered Funds LLC now owns 6,515 shares of the company’s stock worth $249,000 after acquiring an additional 749 shares in the last quarter. EverSource Wealth Advisors LLC lifted its stake in Enovis by 125.4% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 1,271 shares of the company’s stock worth $40,000 after acquiring an additional 707 shares in the last quarter. Finally, Amundi lifted its stake in Enovis by 24,405.0% during the 2nd quarter. Amundi now owns 9,802 shares of the company’s stock worth $328,000 after acquiring an additional 9,762 shares in the last quarter. Institutional investors and hedge funds own 98.45% of the company’s stock.

Enovis Company Profile

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.